Skip to main
IKT
IKT logo

Inhibikase Therapeutics (IKT) Earnings Dates & Reports

Inhibikase Therapeutics (IKT) Most Recent Earnings

Report DateMay 14, 2025
Period EndingQ1 2025
Est. EPS-$0.11
Actual EPS-$0.15
EarningsMiss

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Inhibikase Therapeutics (IKT) Earnings per Share (EPS) History

Signup for full access
Browse free

Inhibikase Therapeutics (IKT) Latest Earnings

The value each IKT share was expected to gain vs. the value each share gained.

Inhibikase Therapeutics (IKT) reported its most recent earnings on May 14, 2025 for Q1 2025, posting earnings per share (EPS) of -$0.15. This exceeded analysts' expectations of -$0.11 by 36.36%, marking a Miss.

For comparison, Inhibikase Therapeutics reported EPS of -$0.73 in the same quarter last year.

The company is expected to announce its next earnings report on 06/27/2025, with analysts projecting an EPS of -$0.10.

Inhibikase Therapeutics (IKT) Earnings History

Earnings
Est. EPSActual EPSSurprise
Q4 2024Mar 27, 2025
-$0.10Next earnings call Jun. 27, 2025
Q1 2025May 14, 2025
-$0.11-$0.15+36.36%
DeckReportListen
Q3 2024Nov 14, 2024
-$0.67-$0.65-2.99%
Q2 2024Aug 15, 2024
-$0.67-$0.66-1.49%
Q1 2024May 16, 2024
-$0.79-$0.73-7.59%
View all

Inhibikase Therapeutics (IKT) Earnings Related Price Changes

Earnings announcements may impact a stock’s price. This table highlights the Inhibikase Therapeutics’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.

Report datePrice 1D beforePrice 1D afterChange
May 14, 2025
Nov 14, 2024
Aug 14, 2024
May 15, 2024

Inhibikase Therapeutics (IKT) Earnings FAQs

Inhibikase Therapeutics (IKT) last reported earnings on May 14, 2025 for Q1 2025, posting an EPS of -$0.15, which Miss the estimate of -$0.11 by 36.36%.

For Q1 2025, Inhibikase Therapeutics (IKT) reported an EPS of -$0.15, missing analysts' estimate of -$0.11 by 36.36%.

For Q1 2025, Inhibikase Therapeutics (IKT) Miss expectations with an actual EPS of -$0.15 vs. an estimated EPS of -$0.11.

Following the last earnings report on May 14, 2025, Inhibikase Therapeutics (IKT)'s stock price moved — from — to —.

The next Inhibikase Therapeutics (IKT) earnings call is scheduled for Jun. 27, 2025, where executives will discuss financial results and outlook.

Inhibikase Therapeutics (IKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.